Fulcrum Therapeutics Inc Up 20.33% To $4.32 After Earnings Beat

Fulcrum Therapeutics Inc (FULC) said before open Tuesday that it lost $0.39 per share in quarter three 2023.

On the revenue line, the company reported $759 thousand, missing estimates by $291 thousand.

In the same quarter a year ago, the company lost $0.51 per share on revenue of $1.2 million.

The stock is up 20.33% to $4.32 after the report.

Fulcrum Therapeutics Inc's revenues declined at a faster pace than earnings.

Wall Street Analysts had an average rating of Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.

Fulcrum Therapeutics Inc has been a strong performer over the past few months, garnering a high Long-Term Technical Rank by InvestorsObserver of 77, putting Fulcrum Therapeutics Inc in the top 25% of stocks. The firm set a 52-week low on April 12, 2023 at $2.25 and set a 52-week high on January 13, 2023 at $15.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability.